Abstract 31P
Background
Incidence rates of breast cancer have been increasing in every country with significant higher proportion of cancer-related mortality particularly in low- and middle-income countries including in Indonesia. Developing novel biomarker is an emerging field in the breast cancer study. Application of a promising minimally-invasive biomarker, circulating microRNA, for additional improvement of diagnosis and therapeutic monitoring in breast cancer is not fully understood.
Methods
We analysed expression of circulating miR-155 in 102 breast cancer patients at diagnosis and after treatment as well as 15 healthy women. Total RNA was extracted from patient’s plasma and microRNA expression was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of circulating miR-155 were compared according to the effect of treatment, clinicopathological variables, and progression-free survival.
Results
In comparison to the healthy women, expression of circulating miR-155 levels were significantly higher (medians were 18.49±19 and 1.28±0.18, respectively; p < 0.0001). The expression levels of miR-155 were significantly reduced after patients completed surgery and chemotherapy (medians were 18.49±19 at diagnosis and 1.32±0.22 after treatment, respectively; p < 0.0001). Patients older than 40 years old expressed higher circulating miR-155 than those younger than 40 years-old (medians were 28.92±22 and 4.19±2.49, respectively; p < 0.0001). No significant different miR-155 expression levels at diagnosis were observed across tumor grades, sizes, subtypes, and clinical stages. Although patients with circulating miR-155 upregulation have longer progression-free survivals, the difference was not statistically significant compared to those without upregulation. (median survivals were 55 vs 43 weeks and Mantel-Cox test p = 0.7).
Conclusions
Expression of circulating miR-155 expression was significantly elevated in breast cancer patients and was decreased after treatment. Therefore, circulating miR-155 was potentially applicable as diagnostic and therapeutic monitoring marker in breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universities Gadjah Mada.
Funding
The Ministry of Research and Higher Education - Republic of Indonesia (PTUPT 1818/UNI/DITLIT/LT/2018 and PPUPT 1987/UNI/DITLIT/LT/2018).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract